Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. Among authors: mortier l. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Maio M, et al. Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Lancet Oncol. 2018. PMID: 29477665 Clinical Trial.
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, Merelli B, Sileni VC, Nyakas M, Haydon A, Dutriaux C, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Larkin J, Tan M, Adnaik SB, Burgess P, Jandoo T, Dummer R. Long GV, et al. Among authors: mortier l. N Engl J Med. 2024 Jun 19. doi: 10.1056/NEJMoa2404139. Online ahead of print. N Engl J Med. 2024. PMID: 38899716
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. Hughes BGM, et al. Among authors: mortier l. J Am Acad Dermatol. 2024 Sep 7:S0190-9622(24)02770-1. doi: 10.1016/j.jaad.2024.06.108. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39245360
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V. Mortier L, et al. Am J Clin Dermatol. 2024 Nov;25(6):987-996. doi: 10.1007/s40257-024-00885-w. Epub 2024 Oct 8. Am J Clin Dermatol. 2024. PMID: 39377880 Free PMC article. Clinical Trial.
Photodynamic Therapy Using a Rose-Bengal Photosensitizer for Hepatocellular Carcinoma Treatment: Proposition for a Novel Green LED-Based Device for In Vitro Investigation.
Lefebvre A, Marhfor S, Baert G, Deleporte P, Grolez GP, Boileau M, Morales O, Vignoud S, Delhem N, Mortier L, Dewalle AS. Lefebvre A, et al. Among authors: mortier l. Biomedicines. 2024 Sep 18;12(9):2120. doi: 10.3390/biomedicines12092120. Biomedicines. 2024. PMID: 39335633 Free PMC article.
Mogamulizumab - induced bone granuloma.
Alaterre C, Philippoteaux C, Toulemonde E, El Maamar Y, Dubois R, Arib I, Carpentier O, Faiz S, Mortier L. Alaterre C, et al. Among authors: mortier l. Joint Bone Spine. 2024 Sep 25:105782. doi: 10.1016/j.jbspin.2024.105782. Online ahead of print. Joint Bone Spine. 2024. PMID: 39332664 No abstract available.
Pustular mycosis fungoides has a poor outcome: a multicentric clinico-pathological and molecular case series study.
Bontoux C, Badrignans M, Afach S, Sbidian E, Mboumba DL, Ingen-Housz-Oro S, Claudel A, Aubriot-Lorton MH, Chong-Si-Tsaon A, Le Masson G, Attencourt C, Dubois R, Beltzung F, Koubaa W, Beltraminelli H, Cardot-Leccia N, Balme B, Nguyen AT, Bagny K, Legoupil D, Moustaghfir I, Denamps J, Mortier L, Hammami-Ghorbel H, Skrek S, Rafaa M, Fougerousse AC, Deschamps T, Dalle S, D'incan M, Chaby G, Beylot-Barry M, Dalac S, Ortonne N. Bontoux C, et al. Among authors: mortier l. Br J Dermatol. 2024 Aug 12:ljae312. doi: 10.1093/bjd/ljae312. Online ahead of print. Br J Dermatol. 2024. PMID: 39133548
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database.
Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, Robert C, Quereux G, Maubec E, Miotti H, Maillard C, Aubin F, Lenormand C, Solbes MN, Joly P, Kachaner I, Lebbé C, Dutriaux C, Saiag P. Mortier L, et al. Eur J Cancer. 2024 Sep;209:114261. doi: 10.1016/j.ejca.2024.114261. Epub 2024 Aug 3. Eur J Cancer. 2024. PMID: 39128185 Free article.
313 results